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with	 dapsone	 and	 nitroso	 dapsone,	 and	 proliferative	 responses	 and	 IFN‐γ	 release	
were	measured.	Dapsone‐	and	nitroso	dapsone‐specific	T‐cell	clones	were	generated	
and	 phenotype,	 function,	 HLA	 allele	 restriction,	 and	 cross‐reactivity	 assessed.	
Dapsone	intermediates	were	characterized	by	mass	spectrometry.
Results: Peripheral	blood	mononuclear	cells	from	six	patients	and	cloned	T	cells	pro‐
liferated	 and	 secreted	Th1/2/22	 cytokines	when	 stimulated	with	dapsone	 (clones:	
n	=	395;	 80%	CD4+	 CXCR3hiCCR4hi,	 20%	CD8+CXCR3hiCCR4hiCCR6hiCCR9hiCCR1





lectively	 to	 the	HLA	protein	 to	 activate	 the	T	 cells	 that	 partic‐
ipate	 in	 the	 adverse	 event.	 Molecular	 docking	 studies	 support	
this	 concept2,3;	 however,	modeling	 data	 have	 to	 be	 interpreted	
with	 caution	as	 the	nature	of	 the	drug‐HLA	protein	 interaction	
and	the	requirement	for	a	specific	peptide	in	the	binding	groove	
has	not	been	determined.	The	most	robust	genetic	associations	
are	 between	 HLA	 class	 I	 alleles	 and	 abacavir	 hypersensitiv‐
ity,4	 flucloxacillin	 liver	 injury	 (both	 HLA‐B*57:01),5	 carbamaze‐
pine‐induced	 Stevens	 Johnson	 syndrome	 (HLA‐B*15:02),6 and 
allopurinol	 hypersensitivity	 (HLA‐B*58:01),7	 and	 in	 each	 case,	
mechanistic	studies	have	shown	that	CD8+	T	cells	are	activated	
when	 the	 drug	 interacts	 with	 the	 relevant	 HLA	 protein.7,8	 For	






tabolite,	 oxypurinol,	 also	 via	 a	 direct	 binding	 interaction	 with	
HLA.	In	contrast,	flucloxacillin‐specific	T	cells	from	patients	with	
liver	 injury	 are	 activated	with	 drug‐protein	 adducts,	 via	 a	 hap‐
ten	mechanism	involving	the	spontaneous	binding	of	the	drug	to	
protein	 and	 antigen	 processing.	 This	 brief	 discussion	 illustrates	
that	 rapid	progress	has	been	made	 in	our	understanding	of	 the	
relationship	between	drug	HLA	binding	and	 the	activation	of	T	






patient	 T	 cells	 via	 a	 hapten	 mechanism12,13;	 however,	 sulfame‐
thoxazole	reactions	are	not	associated	with	a	specific	HLA	allele.	
Thus,	we	recently	synthesized	the	nitroso	metabolite	of	dapsone	
and	 studied	 the	 priming	 of	 naïve	 T	 cells	 from	 healthy	 donors.15 
Dapsone	contains	a	sulfone	group	that	 links	two	aromatic	amine	
moieties.	Oxidative	metabolism	of	 the	amine	groups	generates	a	
hydroxylamine.	 The	 hydroxylamine	 undergoes	 spontaneous	 oxi‐
dation	to	form	nitroso	dapsone,	which	binds	covalently	to	cellular	





































troso	 dapsone‐responsive	 CD4+	 and	 CD8+	 T	 cells	 from	 hypersensitive	 patients.	
Discovery	of	HLA‐B*13:01‐restricted	CD8+	T‐cell	responses	indicates	that	drugs	and	
their	reactive	metabolites	participate	in	HLA	allele‐linked	forms	of	hypersensitivity.
K E Y W O R D S
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was	 conducted	on	 the	back	of	 patients	with	 dapsone	 (0.1%‐25%).	
The	patch	was	removed	after	48	hours.	Results	were	recorded	after	
a	 further	 24	hours	 to	 exclude	 any	 false‐positive	 responses	 result‐
ing	 from	 the	 patch	 tape.	 The	 study	 was	 approved	 by	 the	 Ethical	
Committee	 of	 the	 Shandong	 Provincial	 Institute	 of	 Dermatology	
and	 Venereology,	 and	 informed	 written	 consent	 was	 obtained.	 A	
material	transfer	agreement	was	signed	prior	to	shipment	of	PBMC	
to	Liverpool.
2.2 | Lymphocyte transformation test and 
PBMC ELIspot
Peripheral	 blood	 mononuclear	 cells	 (1.5	×	105	cell/well)	 from	 hy‐
persensitive	patients	and	control	donors	were	incubated	with	dap‐
sone	(125‐500	µmol/L),	nitroso	dapsone	(10‐40	µmol/L),	rifampicin	
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terms	of	cellular	phenotype	(CD,	TCR	Vβ,	and	chemokine	receptors	
[flow	 cytometry]),	 secretion	 of	 cytokines	 and	 cytolytic	 molecules	
(ELIspot),	antigen	specificity	(dose‐response	studies	and	cross‐reac‐
tivity	with	 structurally‐related	 compounds	 [3H]thymidine	 uptake]),	
pathways	of	activation	(antigen‐presenting	cell	pulsing	experiments,	
fixation	of	antigen‐presenting	cells	to	block	processing,	and	addition	
of	 glutathione	 to	 block	 drug	metabolite	 protein	 binding),	 and	 the	




All	 statistical	 analysis	 (one‐way	 ANOVA	 unless	 stated	 otherwise)	
was	performed	using	SigmaPlot	12	software	(*P	<	0.05).
3  | RESULTS
3.1 | Patch testing and in vitro activation of 
hypersensitive patient PBMC





[SI]	 2	 or	 above)	 and/or	 IFN‐γ	 secretion	 were	 also	 detected	 with	
PBMC	from	 the	3	patch	 test‐negative	patients,	while	nitroso	dap‐
sone	responses	were	detected	in	2	patients	(Figure	1B‐D).	Of	note,	
patient	 7	 displayed	 a	 negative	nitroso	dapsone	 lymphocyte	 trans‐
formation	 test	 response	 on	 initial	 testing	 (Figure	 1B)	 and	 a	 weak	
response	 when	 the	 assay	 was	 repeated	 (Figure	 1D).	 PBMC	 were	




3.2 | Dapsone and nitroso dapsone activate 
CD4+ and CD8+ clones
A	 total	 of	 1334	 and	 1374	 CD4+	 and	 CD8+	 clones,	 respectively,	
were	expanded	from	dapsone	and	nitroso	dapsone	T‐cell	lines	from	
patients	5,	6,	 and	8;	626	CD4+	 clones	displayed	 reactivity	 against	
dapsone	or	nitroso	dapsone	(Figure	S2).	Dapsone‐	and	nitroso	dap‐
sone‐specific	CD8+	 clones	were	generated	 in	 lower	numbers;	168	
were	activated	with	either	 the	drug	or	drug	metabolite.	Dapsone‐	
and	 nitroso	 dapsone‐responsive	 CD4+	 and	 CD8+	 clones	were	 de‐
tected	in	equal	numbers	(Table	2).
TA B L E  1  Patients’	demographics	and	details	of	the	hypersensitivity	reaction
Patient ID Gender Age (years) Medication history
Onset of 
symptoms (days) Clinical presentation Skin patch test










5 Male 39 Dapsone,	rifampin,	
and	clofazimine
30 Fever +
6 Male 41 Dapsone,	rifampin,	
and	clofazimine.
48 Fever,	rash,	and	lymphadenopathy +
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One	 hundred	 and	 two	 well‐growing	 clones	 were	 selected	
for	 dose‐titration	 studies	 and	 the	 analysis	 of	 cytokine	 secretion.	
Proliferative	 responses	 were	 detected	 with	 3	 well‐tolerated	 con‐





(Figure	2).	 Table	 S3	 shows	 the	percentage	of	 dapsone	 (DDS)‐	 and	
nitroso	dapsone	(DDS‐NO)‐responsive	CD4+	and	CD8+	clones	that	
secrete	individual	cytokines.
3.3 | Dapsone‐ and nitroso dapsone‐responsive 
CD4+ and CD8+ clones display three distinct 
patterns of cross‐reactivity
Sixty‐three	 dapsone‐	 and	 98	 nitroso	 dapsone‐responsive	 CD4+ 
and	 CD8+	 clones	 were	 assayed	 for	 cross‐reactivity.	 When	 all	 of	
the	dapsone‐responsive	clones	were	assessed	 together,	 low	 levels	
of	 proliferation	 were	 observed	 with	 nitroso	 dapsone	 (Figure	 3A).	
The	maximum	concentration	of	nitroso	dapsone	used	was	10	times	
lower	than	the	dapsone	concentration.	Analysis	of	individual	clones	











Dapsone‐	 and	 nitroso	 dapsone‐responsive	 clones	 were	 also	
stimulated	 to	 proliferate	 with	 dapsone	 hydroxylamine;	 however,	





The	 stability	 of	 nitroso	dapsone	 in	 the	proliferation	 assay	was	
assessed.	Nitroso	dapsone	was	 converted	 rapidly	 to	 azoxy	dimers	
and	the	parent	compound.	Both	compounds	were	detectable	within	
10	minutes.	 After	 2	days,	 50%	 of	 nitroso	 dapsone	 had	 been	 con‐
verted	to	dapsone	(Figure	3D‐E).
3.4 | Cross‐reactive clones are activated 
with equivalent concentrations of dapsone and 
nitroso dapsone
Six	 strong	 and	 weakly	 cross‐reactive	 clones	 were	 incubated	 with	
dapsone	and	nitroso	dapsone	at	concentrations	of	0.1‐100	µmol/L	
to	define	the	minimum	stimulatory	concentrations	of	the	two	com‐
pounds.	 Clones	 were	 stimulated	 to	 proliferate	 with	 equivalent	
concentrations	 of	 each	 compound	 irrespective	 of	 the	 extent	 of	
cross‐reactivity	(Figure	4).
3.5 | Dapsone‐ and nitroso dapsone‐responsive 
CD4+ and CD8+ clones expressing multiple TCR Vβ 
chains display distinct chemokine receptor profiles
Dapsone‐	and	nitroso	dapsone‐responsive	CD4+	and	CD8+	clones	
expressed	single,	but	variable	TCR	Vβ	chains	(Figure	S4A),	with	no	
clear	 differences	 discernible	when	 CD4+	 and	 CD8+	 or	 dapsone‐	
and	nitroso	dapsone‐responsive	clones	were	compared.	Dapsone‐	
and	 nitroso	 dapsone‐responsive	 CD4+	 clones	 expressed	 high	
Phenotype and drug 
specificity







CD4+,	DDS+ 236 176 74.58
CD8+,	DDS+ 245 29 11.84
CD4+,	DDS‐NO+ 384 210 54.69
CD8+,	DDS‐NO+ 304 54 17.76
Patient	6
CD4+,	DDS+ 177 76 42.94
CD8+,	DDS+ 178 14 7.87
CD4+,	DDS‐NO+ 208 57 27.40
CD8+,	DDS‐NO+ 285 15 5.26
Patient	5
CD4+,	DDS+ 180 64 35.56
CD8+,	DDS+ 170 36 21.18
CD4+,	DDS‐NO+ 149 43 28.86
CD8+,	DDS‐NO+ 192 20 10.42
TA B L E  2  Phenotype	and	drug	
specificity	of	T‐cell	clones	generated	from	
dapsone	hypersensitive	patients
     |  7ZHAO et Al.
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levels	 of	 the	 chemokine	 receptors	 CXCR3	 and	CCR4.	 The	 CD8+ 
clones	expressed	CXCR3	and	CCR4	alongside	CCR10,	CCR9,	and	
CCR6	(Figure	S4B).
3.6 | HLA‐restricted activation of dapsone‐ and 
nitroso dapsone‐responsive clones ensues via 
different mechanisms
Stimulation	 of	 dapsone‐	 and	 nitroso	 dapsone‐responsive	 CD4+ and 
CD8+	 clones	 was	 dependent	 on	 the	 presence	 of	 antigen‐present‐
ing	 cells	 (Figure	5A).	Use	of	blocking	antibodies	 revealed	 that	CD4+ 
and	 CD8+	 proliferative	 responses	 to	 dapsone	 and	 nitroso	 dapsone	
were	HLA	class	 II	 and	 I	 restricted,	 respectively	 (Figure	5B).	Fixation	
of	antigen‐presenting	cells	with	glutaraldehyde	had	no	effect	on	the	
activation	of	CD4+	or	CD8+	clones	with	dapsone.	In	contrast,	antigen‐
presenting	 cell	 fixation	 reduced	 the	 extent	 of	 proliferation	with	 the	
nitroso	metabolite	 (Figure	6A).	The	 residual	 response	detected	with	
nitroso	dapsone	and	fixed	antigen‐presenting	cells	relates	to	the	con‐
version	of	nitroso	dapsone	to	dapsone	in	culture.





for	 0.5‐2	hours	 did	 not	 activate	 the	 dapsone‐responsive	 CD4+ or 
CD8+	clones.
Figure	 S5A	 compares	 the	 level	 of	 nitroso	 dapsone	 glutathi‐
one	adducts	formed	in	the	cell	culture	assay	in	the	presence	and	
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absence	 of	 exogenous	 glutathione.23,24	 Adducts	 were	 formed	





proliferative	 response,	 while	 the	 response	 to	 nitroso	 dapsone‐
pulsed	 antigen‐presenting	 cells	was	 completely	 blocked	 (Figure	
S5B).
3.7 | Dapsone and nitroso dapsone bind with a 
degree of selectively to HLA‐B*13:01 to activate 
certain CD8+ T‐cell clones
EBV‐transformed	 B	 cells	 were	 generated	 from	 9	 healthy	 do‐
nors	 expressing	 HLA	 alleles	 with	 >90%	 sequence	 homology	 to	
HLA‐B*13:01.	HLA	typing	of	the	healthy	donors	 is	shown	in	Table	
S2.	 The	 B‐cell	 lines	 were	 used	 to	 explore	 the	 requirement	 for	
HLA‐B*13:01	in	dapsone‐	and	nitroso	dapsone‐specific	CD8+	T‐cell	









































































CD8+ (n = 16)
Nitroso-dapsone clones
CD4+ (n = 20)
CD8+ (n = 22)
(A) (B)

















































CD8+ (n = 3)
CD4+ (n = 3)
CD8+ (n = 6)
CD4+ (n = 4)
Vehicle Dapsone Nitroso dapsone
     |  11ZHAO et Al.








































































































































































1 2 3 4 5
Dapsone clones
CD8+ (n = 16)
Nitroso-dapsone clones
CD4+ (n = 9)
CD8+ (n = 19)
(A) (B)


























Control APC Fixed APCN rma
Pulsed APC (h) Pulsed APC (h) Pulsed APC (h) Pulsed APC (h)
Pulsed APC (h) Pulsed APC (h) Pulsed APC (h) Pulsed APC (h)

























Clone 1 Clone 2 Clone 3 Clone 4
Clone 1 Clone 2 Clone 3 Clone 4
Clone 1 Clone 2 Clone 3 Clone 4
Clone 1 Clone 2 Clone 3 Clone 4
12  |     ZHAO et Al.
activation.	Autologous	antigen‐presenting	cells	and	antigen	present‐
ing	from	1	additional	patients	were	used	as	comparators.





metabolite	 only	 in	 the	 presence	 of	 autologous	 antigen‐presenting	
cells.	Despite	this,	30%‐40%	of	CD8+	clones	displayed	a	degree	of	
HLA‐B*13:01	allele	restriction.	Figure	7A,B	shows	3	clones	(1	dap‐
sone‐	 and	 2	 nitroso	 dapsone‐responsive)	 that	 were	 stimulated	 to	
proliferate	 exclusively	 in	 the	presence	of	 dapsone	or	 nitroso	dap‐
sone	 and	 antigen‐presenting	 cells	 expressing	HLA‐B*13:01.	 Three	
additional	 clones	 (1	 dapsone‐	 and	 2	 nitroso	 dapsone‐responsive)	
are	shown	that	were	activated	in	the	presence	of	antigen‐present‐














tial	 to	 disrupt	 immune	 regulatory	 pathways	 through	 the	 provision	
of	danger	signals.27	However,	the	most	direct	evidence	linking	drug	
metabolism	to	the	development	of	hypersensitivity	is	the	detection	
of	halothane‐specific	antibodies	 in	patients	with	 liver	failure28 and 
the	 observation	 that	 halothane	 protein	 adducts	 activate	 T	 cells.29 
Furthermore,	halothane	derivatives	that	form	lower	 levels	of	reac‐
tive	metabolite	are	associated	with	a	decreased	risk	of	liver	injury.30 
To	 explore	whether	metabolites	 activate	 hypersensitive	 patient	 T	
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cells	in	vitro, co‐culture	strategies	have	been	developed	using	micro‐














exclusively	 on	 the	 interaction	 between	 parent	 drug	 and	 the	 HLA	
molecule.	This	is	because	the	parent	drug	is,	for	the	most	part,	the	
only	reagent	available	for	in	vitro	cell	culture	studies.	The	observa‐






drug	 as	 hypersensitivity	 reactions	 in	 patients	 are	 strongly	 linked	
to	 the	expression	of	HLA‐B*13:01,19	 the	 reactive	nitroso	metabo‐






Six	 HLA‐B*13:01+	 patients	 that	 developed	 hypersensitivity	
while	 receiving	 dapsone	 in	 combination	 with	 rifampicin	 and	 clo‐
fazimine	 were	 recruited	 to	 the	 study.	 Three	 displayed	 a	 positive	
patch	 test	 response	 to	 dapsone.	 PBMC	 from	 all	 six	 patients	were	
stimulated	to	proliferate	and/or	secrete	IFN‐γ	after	stimulation	with	
dapsone	or	the	nitroso	metabolite.	The	strongest	in	vitro	responses	
were	 seen	 in	 the	 patients	 with	 the	 positive	 patch	 test	 response,	
and	these	patients	were	selected	for	serial	dilution	experiments	to	
search	for	drug‐	and	drug	metabolite‐responsive	T‐cell	clones.	CD4+ 
and	CD8+	 subpopulations	were	purified	before	plating	 single	 cells	
























25%‐50%	of	 CD4+	 and	CD8+	 clones	were	 classified	 as	 highly	
specific	as	they	were	only	activated	with	one	compound	(either	the	
parent	drug	or	metabolite	 [Figure	3B]).	This	 confirms	 that	T	cells	
recognize	and	respond	selectively	to	the	two	different	forms	of	the	
dapsone	antigen.	Dapsone	has	an	unusual	structure	in	that	the	two	








When	 using	 optimum	 concentrations	 of	 dapsone	
(100‐500	µmol/L)	 and	 nitroso	 dapsone	 (5‐20	µmol/L)	 to	 activate	
CD4+	 and	CD8+	T	 cells,	 clones	displaying	high	 (ie,	 at	 least	50%	of	
the	 response	 detected	with	 the	 opposite	 compound)	 and	 low	 (ie,	
10%‐50%	of	 the	 response	detected	with	 the	opposite	 compound)	
levels	of	cross‐reactivity	were	also	detected.	The	majority	of	dap‐
sone‐responsive,	 cross‐reactive	 CD4+	 and	 CD8+	 clones	 displayed	
low	 levels	 of	 cross‐reactivity	 with	 nitroso	 dapsone.	 Using	 quanti‐
tative	 mass	 spectrometry,	 we	 were	 able	 to	 demonstrate	 that	 the	
nitroso	metabolite	is	reduced	to	dapsone	in	the	2‐day	proliferation	
assay.	Thus,	clones	incubated	with	30	µmol/L	nitroso	dapsone	were	
exposed	 to	 2.5‐15	µmol/L	 of	 the	 parent	 drug,	 which	 stimulates	 a	
suboptimal	T‐cell	proliferative	response.	In	contrast,	the	majority	of	
cross‐reactive	 nitroso	 dapsone‐responsive	CD4+	 and	CD8+	 clones	
displayed	high	levels	of	cross‐reactivity	with	100‐500	µmol/L	dap‐
sone.	To	investigate	the	response	profiles	further,	a	panel	of	cross‐









tides	 play	 a	 less	 important	 role	 in	 the	 triggering	 of	 cross‐reactive	
TCR.
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Given	that	clones	displaying	reactivity	toward	dapsone	and/or	
the	nitroso	metabolite	were	detected,	it	was	important	to	define	







dapsone	activates	T	 cells	 through	a	direct	 interaction	with	HLA	





tion	of	 dapsone	 in	 the	proliferation	 assay.	 The	drug‐specific	 ac‐
tivation	 of	 clones	 from	dapsone	 hypersensitive	 patients	 by	 two	
pathways	 has	 important	 implications	 for	 the	 future	 structural	
analysis	of	how	dapsone	and	nitroso	dapsone	interacts	with	HLA	




not	 activated	 with	 dapsone‐pulsed	 antigen‐presenting	 cells.	 In	
contrast,	6	out	of	the	8	nitroso	dapsone‐responsive	clones	tested	
were	 activated	 with	 nitroso	 dapsone‐pulsed	 antigen‐presenting	
cells	and	 the	strength	of	 the	 induced	response	was	 the	same	as	

















In	 the	 next	 section	 of	 the	 project,	 antigen‐presenting	 cells	







dapsone	 stimulated	 a	 proliferative	 response	 in	 the	 presence	 of	
multiple	 antigen‐presenting	 cells	 expressing	 different	HLA‐B	 al‐
leles).25	Other	 clones	were	only	 activated	 in	 the	presence	of	ni‐
troso	dapsone	and	autologous	antigen‐presenting	cells.	However,	
a	 panel	 of	 clones	 were	 selectively	 activated	 with	 dapsone	 or	
nitroso	 dapsone	 in	 the	 presence	 of	 antigen‐presenting	 cells	 dis‐
playing	HLA‐B*13:01.	 Cross‐reactivity	was	 observed	 for	 several	
of	these	clones;	however,	no	predominant	TCR	Vβ	receptors	were	
expressed.	This	 indicates	that	both	the	parent	drug	and	reactive	
metabolite	 interacts	with	HLA‐B*13:01	 to	activate	certain	CD8+ 
clones.	We	are	therefore	synthesizing	designer	nitroso	dapsone‐
modified	 HLA‐B*13:01	 binding	 peptides	 and	 conducting	 struc‐
tural	analyses	to	compare	the	binding	interaction	of	dapsone	and	
nitroso	dapsone	with	HLA‐B*13:01.
Different	 forms	 of	 drug	 hypersensitivity	 reaction	 are	 asso‐
ciated	with	 the	 secretion	of	 a	 diverse	panel	 of	 cytokines	 from	T	
cells.41	Thus,	ELIspot	was	used	to	profile	cytokine	secretion	from	
dapsone‐	and	nitroso	dapsone‐stimulated	clones.	CD4+	and	CD8+ 
clones	 secreted	 the	 same	 panel	 of	 cytokines	 when	 stimulated	
with	dapsone	or	nitroso	dapsone,	but	expressed	distinct	chemo‐




profile	 has	 now	 been	 detected	with	 dapsone,	 sulfamethoxazole,	
and piperacillin.42,43	 It	 is	 possible	 that	 this	 profile	 relates	 to	 the	
long‐term	 in	 vitro	 culture	 of	 clones;	 thus,	 a	 future	 study	 explor‐
ing	the	cytokine	profile	in	affected	tissues	would	be	appropriate.	
The	 chemokine	 receptors	 displayed	on	dapsone‐	 or	 nitroso	dap‐
sone‐responsive	CD4+	clones	were	restricted	to	CXCR3	and	CCR4.	
In	 contrast,	 CD8+	 clones	 also	 expressed	 CCR6,	 9,	 and	 10.	 CCR4	
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